Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 10/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 10/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837177 | 1.00 | POLB (0.44) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL4121405 | 1.00 | POLB (0.44) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL2692852 | 0.88 | PIM2 (0.43) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL4127327 | 0.87 | PIM1 (0.51) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL2836092 | 0.87 | PIM1 (0.51) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL2836090 | 0.87 | PIM1 (0.51) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL13707663 | 0.86 | POLB (0.45) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL16587844 | 0.82 | POLB (0.49) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL4126874 | 0.82 | POLB (0.46) | POLBNPC1RAB9ATRPV1ROCK2 | |
| SCHEMBL16506010 | 0.82 | POLB (0.46) | POLBNPC1RAB9ATRPV1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9556197-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3036238-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Corporation (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2935270-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014033630-A1 | NOVEL AMINOTHIAZOLE CARBOXAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| EP-2681195-A1 | NOVEL KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2262802-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012120428-A1 | NOVEL KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| EP-2262802-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190716-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | POLB 2138/4885NPC1 3172/4885RAB9A 2996/4885 |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | POLB 1544/4885NPC1 1582/4885RAB9A 3326/4885 |
| US-10000507-B2 | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors | PIM1, PIM2, PIM3 | POLB 2138/4885NPC1 3172/4885RAB9A 2996/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | POLB 2138/4885NPC1 3172/4885RAB9A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.